BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014. BIND Therapeutics Inc (NASDAQ:BIND) stock performance was 7.75% in last session and finished the day at $12.93. Traded volume was 259,387million shares in the last session and the average … Continue reading Biotech Volatile Stocks: BIND Therapeutics (NASDAQ:BIND), Oncomed Pharmaceuticals Inc (NASDAQ:OMED), Advaxis (NASDAQ:ADXS), Enzon Pharmaceuticals Inc (NASDAQ:ENZN)